CoChat

Preliminary evidence for developing safe and efficient fecal microbiota transplantation as potential treatment for aged related cognitive impairments

Open access
Chen, Xiaoxia, Zhang, Wanling, Lin, Zhijun, Zheng, Chunyan, Chen, Shufang, Zhou, Haihong, Liu, Zhou · 2023 · Frontiers in Cellular and Infection Microbiology

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Background: Recent studies have reported that gut microbiota is closely associated with cognitive fuction. Fecal microbiota transplantation (FMT) may be a potential treatment for cognitive impairment, but its efficacy in patients with cognitive impairment is unknown. Objectives: This study aimed to investigate the safety and efficacy of FMT for cognitive impairment treatment. Methods: Five patients aged 54–80 years (three women) were enrolled in this single-arm clinical trial from July 2021 to May 2022. The Montreal Cognitive Assessment-B (MoCA-B), Activities of Daily Living (ADL), and the cognitive section of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) were assessed at days 0, 30, 60, 90, and 180. Additionally, stool and serum samples were obtained twice before FMT was administered and six months after the treatment. The structure of fecal microbiota was analyzed by 16S RNA gene sequencing. Serum samples were analyzed for metabolomics and lipopolysaccharide (LPS)-binding proteins by liquid chromatography-mass spectrometry and enzyme-linked immunosorbent assay, respectively. Safety was assessed based on adverse events, vital signs, and laboratory parameters during FMT and the follow-up period. Results: The MoCA, ADL, and ADAS-Cog scores of patients with mild cognitive impairment (patients C and E) after FMT were improved or maintained compared with those before transplantation. However, patients with severe cognitive impairment (patients A, B, and D) had no worsening of cognitive scores. Fecal microbiota analysis showed that FMT changed the structure of gut microbiota. The results of serum metabolomics analysis suggested that there were significant changes in the serum metabolomics of patients after FMT, with 7 up-regulated and 28 down-regulated metabolites. 3b,12a-dihydroxy-5a-cholanoic acid, 25-acetylvulgaroside, deoxycholic acid, 2(R)-hydroxydocosanoic acid, and P-anisic acid increased, while bilirubin and other metabolites decreased. KEFF pathway analysis indicated that the main metabolic pathways were bile secretion and choline metabolism in cancer. No adverse effects were reported throughout the study. Conclusions: In this pilot study, FMT could maintain and improve cognitive function in mild cognitive impairment by changing gut microbiota structure and affecting serum metabolomics. Fecal bacteria capsules were safe. However, further studies are needed to evaluate the safety and efficacy of fecal microbiota transplantation. ClinicalTrials.gov Identifier: CHiCTR2100043548.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcimb.2023.1103189

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Changes in cognition and ability of daily living scores before and after FMT. (A) The changes of MoCA in patients before and after FMT. (B) The changes of ADAS-Cog in patients before and after FMT. (C) The changes of ADL in patients before and after FMT. FMT, Fecal microbiota transplantation.
Figure 1 Changes in cognition and ability of daily living scores before and after FMT. (A) The changes of MoCA in patients before and after FMT. (B) The changes of ADAS-Cog in patients before and after FMT. (C) The changes of ADL in patients before and after FMT. FMT, Fecal microbiota transplantation.CC BY · PubMed Central
Figure 2 Results of 16S rRNA high-throughput sequencing analysis of gut microbiota before and after FMT. (A) Alpha diversity analysis of gut microbiota in patients before and after FMT. (B) PCA diversity analysis of gut microbiota in patients before and after FMT. (C) PCoA analysis of gut microbiota in patients before and after FMT. (D) OTU Venn diagram of gut microbiota in patients before and after FMT. (E) Community composition analysis of gut microbiota in patients before and after FMT. (F) Heatmap of gut microbiota in patients before and after FMT. (G, H) LEfSe analysis of gut microbiota in patients before and after FMT.
Figure 2 Results of 16S rRNA high-throughput sequencing analysis of gut microbiota before and after FMT. (A) Alpha diversity analysis of gut microbiota in patients before and after FMT. (B) PCA diversity analysis of gut microbiota in patients before and after FMT. (C) PCoA analysis of gut microbiota in patients before and after FMT. (D) OTU Venn diagram of gut microbiota in patients before and after FMT. (E) Community composition analysis of gut microbiota in patients before and after FMT. (F) Heatmap of gut microbiota in patients before and after FMT. (G, H) LEfSe analysis of gut microbiota in patients before and after FMT.CC BY · PubMed Central
Figure 3 Heatmap of serum metabolomics correlation before and after FMT. (A) OPLS-DA analysis of cation profiles. (B) OPLS-DA analysis of anion table.
Figure 3 Heatmap of serum metabolomics correlation before and after FMT. (A) OPLS-DA analysis of cation profiles. (B) OPLS-DA analysis of anion table.CC BY · PubMed Central
Figure 4 Volcano map of serum metabolomics before and after FMT. (A) Volcano map of cation surface. (B) Volcano diagram of anion table.
Figure 4 Volcano map of serum metabolomics before and after FMT. (A) Volcano map of cation surface. (B) Volcano diagram of anion table.CC BY · PubMed Central
Figure 5 Comparison of serum metabolites before and after FMT. Box charts showed statistical difference in the 4-Hydroxypheoxyacetate (A), Phloracetophenone (B), 4-hydroxy-5-(3,4,5-trihydroxyphenyl)pentanoic acid (C), Alpha-Furyl methyl diketone (D), Xi-2,3-Dihydro-3, 5-dihydroxy-6-methyl-4H-pyran-4-one (E), Bilirubin (F), 6-(hydroxymethyl)-7-methoxy-2H-chromen-2-one (G), Taurochenodeoxycholate-7-sulfate (H), 1-arachidonoyl-2-hydroxy-sn-glycero-3-phosphate (I), LysoPA(0.0/18:2(9Z, 12Z)) (J), C75 (K), MG(0:0/18:4(6Z,9Z,12Z,15Z)/0:0) (L), 3-hydroxytetradecanoyl carnitine (M), Alpha-Triticene (N), Squamostanal A (O), 3b,12a-Dihydroxy-5a-cholanoic acid (P), 25-Acetylvulgaroside (Q), Deoxycholic acid (R), 2(R)-hydroxydocosanoic acid (S), P-Anisic acid (T).
Figure 5 Comparison of serum metabolites before and after FMT. Box charts showed statistical difference in the 4-Hydroxypheoxyacetate (A), Phloracetophenone (B), 4-hydroxy-5-(3,4,5-trihydroxyphenyl)pentanoic acid (C), Alpha-Furyl methyl diketone (D), Xi-2,3-Dihydro-3, 5-dihydroxy-6-methyl-4H-pyran-4-one (E), Bilirubin (F), 6-(hydroxymethyl)-7-methoxy-2H-chromen-2-one (G), Taurochenodeoxycholate-7-sulfate (H), 1-arachidonoyl-2-hydroxy-sn-glycero-3-phosphate (I), LysoPA(0.0/18:2(9Z, 12Z)) (J), C75 (K), MG(0:0/18:4(6Z,9Z,12Z,15Z)/0:0) (L), 3-hydroxytetradecanoyl carnitine (M), Alpha-Triticene (N), Squamostanal A (O), 3b,12a-Dihydroxy-5a-cholanoic acid (P), 25-Acetylvulgaroside (Q), Deoxycholic acid (R), 2(R)-hydroxydocosanoic acid (S), P-Anisic acid (T).CC BY · PubMed Central
Figure 6 VIP analysis and HMDB compound classification of serum metabolomics before and after FMT. (A) VIP analysis of serum metabolomics before and after FMT. (B) Compound classification map of serum metabolomics before and after FMT. (C) KEGG pathway analysis of serum metabolomics in patients before and after FMT.
Figure 6 VIP analysis and HMDB compound classification of serum metabolomics before and after FMT. (A) VIP analysis of serum metabolomics before and after FMT. (B) Compound classification map of serum metabolomics before and after FMT. (C) KEGG pathway analysis of serum metabolomics in patients before and after FMT.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. Yang, 2021, Altered fecal microbiota composition in individuals who abuse methamphetamine, Sci. Rep., 11, 1, 10.1038/s41598-021-97548-1 · DOI

Cited by

See all 55

Metadata

Authors
Chen, X., Zhang, W., Lin, Z., Zheng, C., Chen, S., Zhou, H., & Liu, Z.
Affiliations
Guangdong Medical College (CN)
Corresponding author
  • Zhou, Haihong
  • Liu, Zhou
Venue
Frontiers in Cellular and Infection Microbiology
Published
2023-04-11
Volume
13
Pages
1103189-1103189
ISSN
2235-2988 (ISSN-L)
OpenAlex
W4364365415
Cited by
55
References
38
Citations by year
2026: 12 · 2025: 25 · 2024: 16 · 2023: 2
FWCI
4.90
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Cellular and Infection Microbiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Natural Science Foundation of Guangdong Province
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
fecal microbiota transplantation, mild cognitive impairment, gut microbiota, serum metabolomics, lipopolysaccharide-binding protein, bile secretion, choline metabolism, cognitive function, treatment safety, Alzheimer's disease, gut-brain axis, deoxycholic acid
MeSH terms
Fecal Microbiota Transplantation, Activities of Daily Living, Feces, Female, Humans, Pilot Projects, Treatment Outcome, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preliminary evidence for developing safe and efficient fecal microbiota transplantation as potential treatment for aged related cognitive impairments. https://app.cochat.ai/papers/10.3389/fcimb.2023.1103189
The paper
Chen, X., Zhang, W., Lin, Z., Zheng, C., Chen, S., Zhou, H., & Liu, Z. (2023). Preliminary evidence for developing safe and efficient fecal microbiota transplantation as potential treatment for aged related cognitive impairments. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1103189

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.